Literature DB >> 3297230

Intravenous indomethacin and oxycone-papaverine in the treatment of acute renal colic. A double-blind study.

P E Jönsson, A M Olsson, B A Petersson, K Johansson.   

Abstract

In a prospective double-blind, cross-over study, 61 patients with acute renal colic were treated with either indomethacin (50 mg) or oxycone-papaverine (5 mg + 50 mg) administered intravenously. For those patients requiring a second injection the drugs were reversed. The intensity of pain was evaluated before and 20 min after each injection according to an analogue visual scale 0 to 100. Both drug regimens provided comparable and significant pain relief; a pain score of less than 20 appeared to be satisfactory and was achieved in almost all cases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297230     DOI: 10.1111/j.1464-410x.1987.tb04833.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  5 in total

1.  The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.

Authors:  Isao Wanajo; Yoshitaka Tomiyama; Mariko Tadachi; Mamoru Kobayashi; Yoshinobu Yamazaki; Masami Kojima; Nobuo Shibata
Journal:  Urol Res       Date:  2005-08-25

Review 2.  Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic.

Authors:  A Holdgate; T Pollock
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

3.  The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle.

Authors:  Abdullah Sivrikaya; Omer Fatih Celik; Nursel Sivrikaya; Guner Kemal Ozgur
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 4.  Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic.

Authors:  Anna Holdgate; Tamara Pollock
Journal:  BMJ       Date:  2004-06-03

5.  [Pain therapy in acute renal colic.].

Authors:  C Tschuschke; S C Müller; L Hertle
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.